Buy Volatus Aerospace ahead of Q2 results, Echelon says

After a tough first quarter, Echelon Capital Markets analyst Rob Goff says things are looking up for Volatus Aerospace (Volatus Aerospace Stock Quote, Chart, News, Analysts, Financials TSX:VOL).

Goff says expectations are set for a strong second half to 2023 for the company.

“As noted, post-Q123 management maintained its 2023 guidance calling for revenue/gross profit at $52.0M/$16.6M with a 32% margin, where contributing factors include large outstanding RFPs, increased military sales, and commercially leveraging its technologies such as the Aerieport and ISR drones,” the analyst said.

Toronto-based Volatus provides integrated drone solutions in North America and globally, with business in the civil, public safety and defense markets and including imaging and inspection, security and surveillance, equipment sales and support and training as well as R&D, design and manufacturing.

In a research update to clients Monday, Goff maintained his “Speculative Buy” rating and one-year price target of $0.90, implying a return of 283 per cent at the time of publication.

Goff thinks VOL will post revenue of $47.1-millionin fiscal 2023 and grow that figure to $66.0-million the following year.

“Following a tough Q123, management left full-year 2023 guidance unchanged while highlighting headwinds that led to lower Q123 and Q223 revenues. While some revenues were arguably delayed, we saw some lost revenues in Q123 but expect to see improvements in Q223. We note the Company’s prior reference to a robust sales pipeline where we are optimistic that it will secure significant wins,” Goff added.

Tagged with: vol
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Gain Therapeutics: this analyst just chopped his target

Roth Capital Partners analyst Boobalan Pachaiyappan lowered his target on Gain Therapeutics (Gain Therapeutics Stock Quote, Chart, News, Analysts, Financials… [Read More]

3 hours ago

WELLSTAR Technologies is off to a great start, this analyst says

WELLSTAR Technologies’ (WELLSTAR Technologies Corp. Stock Quote, Chart, News, Analysts, Financials TSXV:WSTR) first quarterly results as a public company exceeded… [Read More]

3 hours ago

This Canadian stock benefits from increased defense spending, analyst says

Volatus Aerospace’s (Volatus Aerospace Stock Quote, Chart, News, Analysts, Financials TSX:FLT) first Canadian Armed Forces contract and growing defence order… [Read More]

9 hours ago

Buy WELL Health Technologies for a double, this analyst says

WELL Health Technologies’ (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) Canadian clinic operations delivered strong third-quarter growth,… [Read More]

12 hours ago

Is Quarterhill (TSX:QTRH) an undervalued stock?

Quarterhill (Quarterhill  Stock Quote, Chart, News, Analysts, Financials TSX:QTRH) remains on track to complete its acquisition of Conduent’s tolling business… [Read More]

13 hours ago

This Canadian biotech stock is undervalued, analyst says

Medicenna Therapeutics’ (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) experimental cancer treatment MDNA11 produced encouraging responses in patients… [Read More]

14 hours ago